Results 251 to 260 of about 118,937 (337)

Evaluation of the treatment effectiveness of oral and intralesional steroids in idiopathic granulomatous mastitis using superb microvascular imaging

open access: yesANZ Journal of Surgery, EarlyView.
Abstract Objectives The objective of this study was to compare the efficacy of oral and intralesional steroid injection in the treatment of idiopathic granulomatous mastitis (IGM) cases with clinical, ultrasonography (US) and Superb microvascular imaging (SMI) findings.
Oğuz Karakayalı   +6 more
wiley   +1 more source

Syndecan-1 as a predictor of vulnerable atherosclerotic plaques. [PDF]

open access: yesFront Cell Dev Biol
Qiu Y   +5 more
europepmc   +1 more source

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post   +4 more
wiley   +1 more source

Associations between intraplaque hemorrhage and other high-risk plaque features in atherosclerotic plaques.

open access: yesNeuroradiol J
Nguyen MT   +8 more
europepmc   +1 more source

Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making?

open access: bronze, 2000
Gerard Pasterkamp   +3 more
openalex   +1 more source

The physiological and pathological effects of sphingolipid metabolism and signaling in the central nervous system

open access: yesBrain Pathology, EarlyView.
Sphingolipids are vital components of cell membranes. Metabolic disruptions of sphingolipids, including ceramide and sphingosine‐1‐phosphate, are linked to neurological disorders. This article summarizes the classification, structure, and metabolic processes of sphingolipids, and the physiological and pathological effects of sphingolipid metabolism and
Tian Li   +7 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy